Core Viewpoint - The approval of the recombinant type I α1 collagen freeze-dried fiber product by the National Medical Products Administration of China marks a significant milestone for the company, enhancing its competitive edge in the skin rejuvenation market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shaanxi Juzhi Biotechnology Co., Ltd., received the Medical Device Registration Certificate for the recombinant type I α1 collagen freeze-dried fiber product [1] - This product is the first recombinant type I natural sequence collagen injectable product approved in China, indicating a breakthrough in the industry [1] Group 2: Market Opportunities - The approval reflects the company's core competencies in technology research and development, as well as industrialization [1] - The new product will diversify the company's product offerings and create new opportunities for business development in the skin rejuvenation market [1] Group 3: Future Plans - The company plans to gradually launch and promote the product according to its business strategy [1] - There will be a focus on collaboration with existing products, brands, and channels to provide consumers with a more diverse experience [1] - The company aims to strengthen its leading position in the health and beauty sector [1]

Core Viewpoint - Juzi Biotechnology (02367.HK) is experiencing significant stock price volatility due to poor sales performance in live streaming, leading to a decline in market confidence and a substantial drop in stock value [1][2] Group 1: Shareholding and Stock Performance - Juzi Holding, the controlling shareholder, purchased 500,000 shares for approximately HKD 19.3 million, increasing its total holdings to 5.85 billion shares, representing 54.61% of the company's issued shares [1] - The company's stock price recently fell from a high of HKD 87.1 per share on May 20 to a low of HKD 56.2 per share by June 9, resulting in a market value loss exceeding HKD 30 billion [1] - The latest stock price is HKD 38.62, with a market capitalization of HKD 41.36 billion [1] Group 2: Financial Performance - Juzi Biotechnology reported a revenue of HKD 3.113 billion for the first half of 2025, a year-on-year increase of 22.5%, and a net profit of HKD 1.182 billion, up 20.6% [2] - The projected revenue for 2024 is HKD 5.538 billion, reflecting a 57.2% year-on-year growth, with a net profit forecast of HKD 2.061 billion, a 42.4% increase [2] - The company has significantly increased its sales and distribution expenses, with a projected expenditure of HKD 2.008 billion in 2024, up 72.51% from HKD 1.164 billion in 2023 [2] Group 3: Market Position and Challenges - Juzi Biotechnology is a leading player in the restructured collagen market, with its brand Kefu Mei achieving rapid growth and becoming a top domestic brand [2] - The company has faced challenges due to ongoing disputes regarding the authenticity of collagen content, which has affected consumer confidence and market perception [1]

Core Viewpoint - The article discusses the competitive landscape in the functional skincare market, focusing on the rivalry between two prominent female entrepreneurs, Fan Daidi from Xi'an and Yang Xia from Shanxi, as they pivot their companies towards the C-end beauty segment, particularly in the context of the recent Double 11 shopping festival [1][12]. Group 1: Market Dynamics - The Double 11 shopping festival has seen a new brand "Tongpin" rapidly rise in popularity, achieving significant sales growth, with its GMV ranking second in Li Jiaqi's live broadcast [1][5]. - Despite the success of Tongpin, the stock price of Juzhi Biological has been declining, hitting a new low of 40.40 HKD per share, with a total market value of 43.3 billion HKD [2]. - Juzhi Biological's stock has faced continuous declines, while Jinbo Biological's stock also fell, indicating a broader trend of market challenges for both companies [2]. Group 2: Brand Development - Tongpin, established in March 2024, focuses on technology-driven skincare solutions and has launched a limited range of products, including five core items [4]. - The brand's rapid sales growth is attributed to its strategic partnerships with top influencers, particularly in live streaming channels [5]. - During the Double 11 event, Tongpin achieved over 20 million RMB in sales, ranking first among new brands on Tmall [5]. Group 3: Corporate Relationships - Tongpin is closely linked to Jinbo Biological, which provides technical support and has several patented ingredients used in Tongpin's products [7]. - Jinbo Biological's founder, Yang Xia, has actively promoted Tongpin, indicating a strategic shift from B-end medical devices to C-end skincare [1][7]. - Jinbo Biological has recently attracted investment from Zhong Shanshan, founder of Nongfu Spring, further solidifying its market position [12]. Group 4: Industry Implications - The competition between Juzhi Biological and Jinbo Biological reflects a broader trend of blurring lines between pharmaceutical and beauty companies in China's functional skincare market [13]. - The outcome of this rivalry will significantly influence the next industry cycle and determine the leading players in the market [13].

Core Insights - A competitive landscape is emerging in the functional skincare market, particularly around the "recombinant collagen" segment, involving two prominent female entrepreneurs, Fan Daidi and Yang Xia, who lead their respective companies, Juzhi Biotechnology and Jinbo Biotechnology [1][12] Company Developments - Jinbo Biotechnology has successfully transitioned from a B2B medical device focus to a B2C functional skincare market, as evidenced by its support for the new brand "Tongping" [2][3] - Tongping, launched in September 2024, has quickly gained traction in the market, achieving significant sales during the Double 11 shopping festival, with a GMV exceeding 20 million yuan in its first appearance on Li Jiaqi's livestream [6][11] - Juzhi Biotechnology's stock has faced challenges, hitting a year-low of 40.40 HKD per share, with a total market capitalization dropping to 43.3 billion HKD [2][3] Market Trends - The functional skincare market is witnessing intensified competition, with new brands like Tongping rapidly gaining market share through strategic partnerships with key influencers [4][6] - The sales performance of Tongping's products, particularly those promoted by Li Jiaqi, indicates a strong consumer response, with several SKUs achieving sales exceeding 100,000 units [6][7] - Jinbo Biotechnology's collaboration with Tongping highlights the blurring lines between pharmaceutical and beauty sectors, reflecting a shift in the industry towards comprehensive competitive strategies [12] Financial Movements - Jinbo Biotechnology is in the process of raising capital through a stock issuance, with plans to issue up to 7.18 million shares at a price of 278.72 yuan per share, aiming to raise up to 2 billion yuan [12]

Core Viewpoint - The competition in the collagen industry is intensifying, with two regional female tycoons leading their respective companies into the spotlight, highlighting a shift from B2B to B2C markets in the beauty sector [2] Group 1: Company Strategies - Juzhi Biotechnology, led by Fan Daidi, was once a benchmark in the industry but is now facing competition from Jinbo Biotechnology, which is entering the consumer skincare market with its new brand "Tongping" [2] - Jinbo's founder, Yang Xia, has made a rare public appearance to support the "Tongping" brand, signaling a strategic shift from medical devices to beauty products [2] Group 2: Market Dynamics - The competition began in e-commerce live streaming, where "Tongping" quickly gained traction, ranking second in GMV growth during Li Jiaqi's first live stream of this year's Double Eleven shopping festival [2] - The entry of Jinbo into the collagen market poses a direct challenge to Juzhi, as both companies utilize similar traffic-driven sales strategies and product types [2] - The ability of Jinbo to leverage its pharmaceutical background to outperform Juzhi will significantly influence the future landscape of the collagen market [2]

Core Viewpoint - The article highlights the declining performance of Juzhibio (巨子生物) and its main brand, Kefu Mei (可复美), during the "Double Eleven" pre-sale period, leading to a significant drop in stock price and market value [3][5]. Company Performance - Juzhibio's stock price fell to a new low of HKD 40.40 per share, with a total market value of HKD 43.3 billion, marking a 53.46% decline from its peak of HKD 86.8 per share in May [3][5]. - Kefu Mei's sales during the "Double Eleven" pre-sale were underwhelming, with a reported GMV of HKD 0.5-0.75 billion on Douyin, down from over HKD 1 billion in the same period last year [3][4]. Market Competition - The market for recombinant collagen products is growing rapidly, with a projected CAGR of 44.93%, expected to reach RMB 2,193.8 billion by 2030 [6]. - Juzhibio's revenue is forecasted to increase from RMB 2.364 billion in 2022 to RMB 5.539 billion in 2024, while its net profit is expected to rise from RMB 696 million to RMB 2.062 billion in the same period [6]. Brand Strategy and Challenges - Kefu Mei has faced challenges due to a previous controversy regarding its collagen stick product, which has negatively impacted its sales performance [3][4]. - Juzhibio's marketing expenses reached HKD 10.58 billion in the first half of the year, accounting for 34.01% of total revenue, as the company seeks to maintain growth amid increasing competition [7].

消息面上，2025年双十一电商大促已经提前启动。华泰证券此前指出，在25Q2面临一定外部因素影响 的背景下，巨子生物上半年收入与利润仍能双增，且盈利能力维持相对稳定，彰显品牌定力与业绩韧 性。双11旺季临近，公司品牌宣传/达人推广等活动有望逐步恢复并带动公司H2增长提速。 巨子生物(02367)再跌超5%，截至发稿，跌5.33%，报50.6港元，成交额6.28亿港元。 值得注意的是，华熙生物9月底表示，已联合国家计量院等多家第三方检测机构对相关企业的相关产品 展开检测，结果几十份检测结果均显示，相关产品中的重组胶原蛋白添加量未达标。华熙生物表 示，"已将数十份检测报告提交国家药品监督管理局。"分析人士称，可复美在今年618电商大促中失 意，市场将重点关注双11期间可复美电商销售表现。 ...

Summary of the Conference Call for Juzi Biotechnology Company Overview - Juzi Biotechnology is a pioneer in the research and production of recombinant collagen, focusing on functional skincare products, medical devices, and functional foods. The company has the most comprehensive collagen molecular library globally and has contributed to the establishment of the first industry standards for recombinant collagen in China [3][4]. Industry Insights - The beauty and skincare industry is experiencing a shift towards differentiated competition, with Juzi leveraging its proprietary recombinant collagen technology through brands like Kefu Mei and Keli Jin. Kefu Mei is seeing rapid growth, while Keli Jin has returned to a growth trajectory after adjustments [2][4]. Key Financial Performance - Juzi Biotechnology projects a 25% revenue growth and a 20% profit growth for the year. The company anticipates strong performance in the second half of the year, supported by collaborations with key influencers for promotional events like Double Eleven [4][14]. Online and Offline Channel Strategy - Online sales account for 75% of total revenue, expected to rise above 80%. The company employs a GTC model for online sales, while offline sales are conducted through a distribution model with lower sales costs. Juzi is expanding its product offerings in pharmacies and hospitals, and has launched a new brand, "Ke Yu," targeting family consumption [2][8][9]. Response to Market Challenges - The company has effectively managed short-term public relations challenges by stabilizing gross sales margins and optimizing cost structures. Collaborations with influencers are strategically planned to avoid significant fluctuations in operating margins [6][11]. Pricing Strategy - During the Double Eleven shopping festival, Juzi maintained stable pricing to prevent negative consumer perceptions regarding brand value. The company selectively participated in promotional activities, ensuring minimal impact on gross margins [7][14]. Product Development and Innovation - Juzi is actively tracking market trends and new ingredients, such as PDR, to enhance its product offerings. The company emphasizes scientific validation and consumer value in its product development strategy, avoiding the release of ineffective products [12][13]. Future Outlook - The company is optimistic about its growth trajectory, particularly in the cosmetics and medical aesthetics sectors. Juzi is focused on steady development, with plans to enhance its online presence and maintain a robust offline foundation. The company is also exploring international markets, albeit at a cautious pace [15][16].

Core Viewpoint - The article discusses the integration of effective skincare and medical aesthetics, highlighting the shift in consumer demand from visible results to verifiable and reproducible outcomes. The emergence of recombinant collagen as a "super ingredient" is noted, with retail scale surpassing 28.6 billion yuan, while the industry faces challenges of unregulated efficacy claims and inconsistent perioperative care standards [2][13]. Summary by Sections Standards and Guidelines - The first domestic standard for recombinant collagen penetration, titled "Detection of Penetration, Degradation, and Promotion of Collagen by Raman Spectroscopy in Humans," was released on September 5, 2025, with Furuida Bio Co., Ltd. as the main drafter [5][14]. - This standard addresses the credibility of ingredient efficacy and clinical care standardization, providing a technical and procedural foundation for the integration of effective skincare and medical aesthetics [3][14]. - The "Medical Aesthetic (Perioperative) Skin Care Guidelines" was also published around the same time, outlining comprehensive skin care protocols from pre-operative to post-operative stages [10][12]. Market Dynamics - The recombinant collagen market has become a core component of effective skincare and medical aesthetics, with a retail scale projected to reach 28.6 billion yuan by 2024, significantly outpacing industry growth rates [13][14]. - The lack of unified standards for product efficacy claims and the inconsistency in perioperative care processes have created a chaotic market environment, indicating a transition from unregulated growth to a more refined approach [13][15]. Furuida Bio's Role - Furuida Bio Co., Ltd. has positioned itself as a leader in the industry by establishing these standards, filling the gap of "no evidence for testing and no benchmarks for evaluation" in the recombinant collagen sector [3][16]. - The company’s strategy involves embedding its products into standardized clinical processes through the "Care Guidelines," while also leveraging the "Detection Standard" to gain consumer trust [16][24]. Brand Development - The high-end medical aesthetic brand "Key C" under Furuida is rapidly gaining market traction, utilizing a "standard + technology + platform" strategy to penetrate the market [17][24]. - Key C has developed a unique "Recombinant Membrane Penetration Engine" that significantly enhances the skin penetration rate of collagen, addressing long-standing industry challenges [19][24]. - The brand's flagship product, "Membrane Penetrating Collagen Essence," has achieved remarkable sales, further solidifying its market presence and brand recognition [19][23]. Future Outlook - With the establishment of these standards and the successful launch of Key C products, Furuida aims to create a comprehensive care solution that spans medical aesthetics and health, positioning itself for significant growth in the global beauty market [24].

Core Viewpoint - The ongoing discussion in the medical aesthetics industry regarding recombinant collagen and hyaluronic acid (HA) has been fueled by a recent article from Huaxi Biological, which challenges the one-sided views presented in some research reports about HA's efficacy and market value [1][2]. Industry Discussion - The debate began when a collagen company compared recombinant collagen and HA in its IPO prospectus, leading to a perception that recombinant collagen has advantages, which was echoed in various research reports [2]. - This perception has caused a misalignment in consumer understanding of HA's benefits and has impacted the market trust in HA, a sector where China holds a competitive edge [2]. - Huaxi Biological emphasizes that the scientific value and anti-aging properties of HA have been validated by numerous studies published in top journals, with a significant increase in research output since 2010 [2]. Research Report Critique - Industry experts note that while it is normal for research reports to focus on emerging technologies, they must be grounded in scientific analysis to avoid skewing perceptions and affecting industry development [3]. - Huaxi Biological's response to certain reports aims to uphold the scientific foundation of the industry and prevent speculative trading from disrupting technological advancements [3]. Challenges in Research Reports - The rapid evolution of capital market trends has led to challenges in the independence and professionalism of some research reports, which may deviate from objective principles [4]. - Some reports exhibit limitations in understanding the HA and collagen industries, lacking thorough analysis of core product mechanisms and scientific validation [4]. - There is a noticeable issue of content homogenization among reports, with many relying on mutual citations rather than original research, which undermines the credibility of their conclusions [4]. Market Influence on Research Independence - Research institutions play a crucial role in information dissemination, and their objectivity is vital, especially when market trends create hot concepts that may lead to superficial analyses [5]. - The balance between short-term market demands and long-term industry growth remains a challenge for research reports [5]. Collaborative Efforts for a Rational Capital Ecosystem - Huaxi Biological advocates for the improvement of research report quality to foster a rational discussion in the capital market and promote scientific rigor [6]. - Enhancing report quality requires collaborative efforts across the industry, emphasizing the need for in-depth field research and firsthand data collection [6]. - Reports should establish a comprehensive analytical framework that includes various data sources to avoid one-sided conclusions and provide investors with a holistic view [6]. Upholding Professional Independence - The core value of research reports lies in their ability to connect industry innovation with value investment through professional analysis [7]. - Reports must respect scientific principles and market dynamics, avoiding oversimplification of complex technologies and refraining from promoting short-term speculation [7].